{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:00:47Z","timestamp":1769684447017,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,10,19]],"date-time":"2001-10-19T00:00:00Z","timestamp":1003449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Early Children's Cancer Group (CCG) trials indicated that the cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) regimen was superior to the LSA<jats:sub>2<\/jats:sub>L<jats:sub>2<\/jats:sub>regimen for non\u2010lymphoblastic (NLB) non\u2010Hodgkin lymphoma (NHL). Studies by other groups suggested that addition of anthracyclines to standard therapies could improve outcome. Therefore, in 1983 CCG initiated study CCG\u2010503, a randomized trial of COMP vs. daunomycin\u2010COMP (D\u2010COMP) in children and adolescents with disseminated NLB NHL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedures<\/jats:title><jats:p>Between December 1983 and April 1990, 404 eligible patients were entered. Patients without central nervous system (CNS) or marrow involvement were randomized to receive COMP (N\u2009=\u2009139) or D\u2010COMP (N\u2009=\u2009145). Randomization was stratified by histology and site of disease. Patients with CNS or marrow involvement (stage IV) were non\u2010randomly treated with D\u2010COMP (N\u2009=\u2009120).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten\u2010year event\u2010free survival in COMP and D\u2010COMP patients was similar: 55\u2009\u00b1\u20094.3% (Estimate\u2009\u00b1\u2009SE) vs. 57\u2009\u00b1\u20094.2% (not significant). Stage I\u2013III patients with large\u2010cell (LC) NHL had worse 10\u2010year event\u2010free survival (EFS) (48\u2009\u00b1\u20094.9%) than those with small non\u2010cleaved cell (SNCC) NHL disease (61\u2009\u00b1\u20093.5%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05 in multivariate analysis), but equivalent survival (65\u2009\u00b1\u20094.7% vs. 63\u2009\u00b1\u20093.5%) due to significantly higher salvage rates in LC patients, especially those failing more than 12 months from diagnosis. Ten\u2010year EFS in stage IV patients was 39\u2009\u00b1\u20095.2%. Addition of daunomycin resulted in higher rates of grade 3\/4 hematologic toxicity and stomatitis, as well as late cardiac\u2010related deaths. The incidence of second malignant neoplasms was 1.0% at 10 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Addition of daunomycin to standard COMP therapy did not improve outcome in pediatric disseminated NLB NHL. Patients with LC disease had a significantly reduced long\u2010term EFS, but were retrieved at a higher rate than patients with SNCC disease, resulting in equivalent long\u2010term survival. Med Pediatr Oncol 2001;37:432\u2013441. \u00a9 2001 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mpo.1226","type":"journal-article","created":{"date-parts":[[2002,9,11]],"date-time":"2002-09-11T00:35:40Z","timestamp":1031704540000},"page":"432-441","source":"Crossref","is-referenced-by-count":39,"title":["Comparison of long\u2010term outcome of children and adolescents with disseminated non\u2010lymphoblastic non\u2010Hodgkin lymphoma treated with COMP or daunomycin\u2010COMP: A report from the Children's Cancer Group"],"prefix":"10.1002","volume":"37","author":[{"given":"Richard","family":"Sposto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna T.","family":"Meadows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Chilcote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Steinherz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Kjeldsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall E.","family":"Kadin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda M.","family":"Termuhlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart E.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,10,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840415)53:8<1695::AID-CNCR2820530813>3.0.CO;2-U"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(83)80204-4"},{"key":"e_1_2_1_4_2","first-page":"537","volume-title":"Principles and Practice of Pediatric Oncology","author":"Magrath I","year":"1993"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303103081003"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.6.1024"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800215)45:4<630::AID-CNCR2820450403>3.0.CO;2-5"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.2.91"},{"key":"e_1_2_1_9_2","first-page":"289","article-title":"Daunomycin plus COMP vs. COMP therapy in childhood non\u2010lymphoblastic lymphomas","volume":"10","author":"Chilcote R","year":"1991","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197801)41:1<303::AID-CNCR2820410142>3.0.CO;2-G"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_1_12_2","first-page":"332","article-title":"Classification, staging, and end results of treatment of childhood non\u2010Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy SB","year":"1980","journal-title":"Sem Oncol"},{"key":"e_1_2_1_13_2","article-title":"Cure model analysis in pediatric cancer: an application to data from the Children's Cancer Group","author":"Sposto R","year":"2001","journal-title":"Statistics in Medicine"},{"key":"e_1_2_1_14_2","volume-title":"The statistical analysis of failure time data","author":"Kalbfleisch JD","year":"1980"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197609)38:3<1043::AID-CNCR2820380302>3.0.CO;2-U"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197601)37:1<123::AID-CNCR2820370119>3.0.CO;2-7"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197707142970202"},{"key":"e_1_2_1_18_2","first-page":"210","article-title":"Total therapy\u2010B for B cell acute lymphocytic leukemia (B\u2010ALL) and Stage III\u2013IV B cell non\u2010Hodgkin's lymphoma (B\u2010NHL)","volume":"2","author":"Bowman PW","year":"1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.963"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800315)45:6<1507::AID-CNCR2820450634>3.0.CO;2-D"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2017"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950240105"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241205"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230502"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.2.186"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.1995.13.8.2023","article-title":"B\u2010cell lineage confers a favorable outcome among children and adolescents with large\u2010cell lymphoma: a Pediatric Oncology Group Study","volume":"13","author":"Hutchison RE","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.1226","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.1226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T19:50:36Z","timestamp":1696708236000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.1226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,19]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1002\/mpo.1226"],"URL":"https:\/\/doi.org\/10.1002\/mpo.1226","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,19]]}}}